- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06164860
The Effect of Ketogenic Diet Versus Mediterranean Diet in Patients With Obesity and Psoriatic Arthritis
December 8, 2023 updated by: VAIA LAMBADIARI, Attikon Hospital
The Effect of Ketogenic Diet Versus Mediterranean Diet on Clinical and Biochemical Markers of Inflammationand in Patients With Obesity and Psoriatic Arthritis
The aim of our study is to compare the effectiveness of Mediterranean diet (MD) with the isocaloric Ketogenic diet (KD) on clinical and biochemical markers of inflammation in patients with obesity, psoriasis (PSO) and psoriatic arthritis (PsA).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Overall, twenty patients with body mass index (BMI) >30 kg/m2, PSO and PsA under constant systematic treatment for at least 3 months will be included in the study.
They will randomly assign to two groups, starting either with MD or KD for a period of 8 weeks.
After a 6-week washout interval, the two groups will cross over to the other type of diet for the same 8-week period.
The primary endpoint is the change in Psoriasis Area and Severity Index (PASI) and the Disease Activity Index for Psoriatic Arthritis (DAPSA) score, 8 weeks after each diet intervention.
Secondary endpoints are changes in biochemical markers of inflammation (IL-6, IL-17, IL-22, IL-23) , in metabolic and anthropometric parameters.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Attiki
-
Athens, Attiki, Greece, 12462
- Vaia Lambadiari
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- age above 18 years
- body mass index (BMI) >30 kg/m2
- diagnosis of psoriasis and psoriatic arthritis under constant systematic treatment with biologic agents and/or synthetic disease-modifying anti-rheumatic drugs (DMARDs) for at least 3 months.
- ΔPASI SCORE<75, with moderate or severe activity in joints ( > 3 swollen &> 3 tender joints ή DAPSA< 14).
Exclusion Criteria:
- participation in another study
- eGFR<60ml/min/1.73m2
- malignancy
- severe hepatic disorder
- HbA1C>10%
- use of glucagon-like-petide-1 analogues
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Group A
started with MD
|
The MD provided 20% proteins, 40% fat and 40% carbohydrates.
Each participant received a brochure with a template of a daily five course (breakfast, lunch, dinner and two snacks) diet plan that provided several options for each meal and was advised to use it as a guide for the 8-week period
The KD provided approximately 34% proteins, 55% fat and 11% carbohydrates.
The macronutrient targets were successfully met by replacing breakfast and two daily snacks with specifically selected food products provided by Evivios Med.
Lunch and dinner were natural protein-rich dishes.
Each participant received accurate teaching and a brochure that incorporated a template of a weekly diet plan from an expert dietitian.
|
Other: Group B
started with KD
|
The MD provided 20% proteins, 40% fat and 40% carbohydrates.
Each participant received a brochure with a template of a daily five course (breakfast, lunch, dinner and two snacks) diet plan that provided several options for each meal and was advised to use it as a guide for the 8-week period
The KD provided approximately 34% proteins, 55% fat and 11% carbohydrates.
The macronutrient targets were successfully met by replacing breakfast and two daily snacks with specifically selected food products provided by Evivios Med.
Lunch and dinner were natural protein-rich dishes.
Each participant received accurate teaching and a brochure that incorporated a template of a weekly diet plan from an expert dietitian.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PASI score
Time Frame: eight weeks
|
The primary endpoint is changes in Psoriasis Area and Severity Index (PASI), 8 weeks after each diet intervention.
|
eight weeks
|
DAPSA score
Time Frame: eight weeks
|
The primary endpoint is changes in Disease Activity Index for Psoriatic Arthritis (DAPSA) score, 8 weeks after each diet intervention.
|
eight weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Interleukins
Time Frame: eight weeks
|
Secondary endpoints were biochemical markers of inflammation (IL-6, IL-17, IL-22, IL-23) 8 weeks after KD compared to 8-weeks MD diet intervention.
|
eight weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 20, 2020
Primary Completion (Actual)
January 31, 2022
Study Completion (Estimated)
December 30, 2023
Study Registration Dates
First Submitted
December 2, 2023
First Submitted That Met QC Criteria
December 8, 2023
First Posted (Estimated)
December 11, 2023
Study Record Updates
Last Update Posted (Estimated)
December 11, 2023
Last Update Submitted That Met QC Criteria
December 8, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 312/01-05-2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity and Psoriasis
-
Federico II UniversityCompletedPlaque-type Psoriasis | Obesity (Body Mass Index >30 kg/m2)Italy
-
Universita di VeronaCompleted
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Rockefeller UniversityTerminatedObesity | PsoriasisUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
Clinical Trials on Meditteranean Diet
-
Laval UniversityDairy Farmers of Canada; Agriculture and Agri-Food CanadaCompleted
-
Tufts Medical CenterCompletedObesity | Cardiovascular Disease | Metabolic Syndrome
-
University of PittsburghCompletedCardiovascular Diseases | ObesityUnited States
-
Hospital Parc Taulí, SabadellHospital Mutua de Terrassa; Consorci Sanitari de TerrassaTerminatedColorectal Cancer | Colon Adenoma | Colon PolypSpain
-
Kaiser PermanenteNational Center for Complementary and Integrative Health (NCCIH)CompletedHypertension | ObesityUnited States
-
Pennington Biomedical Research CenterNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruiting
-
Pennington Biomedical Research CenterThe Cleveland ClinicRecruiting
-
Indiana University School of MedicineNational Institutes of Health (NIH)Completed
-
Burke Rehabilitation HospitalCompletedStroke | Ischemic StrokeUnited States
-
Oregon Health and Science UniversityCompletedTrifunctional Protein Deficiency | Carnitine Palmitoyltransferase 2 Deficiency | Very Long-chain Acyl-CoA Dehydrogenase Deficiency | Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency